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Hemopoietic cells, apparently committed to one line-
age, can be reprogrammed to display the phenotype of
another lineage. The J2E erythroleukemic cell line has
on rare occasions developed the features of monocytic
cells. Subtractive hybridization was used in an attempt
to identify genes that were up-regulated during this
erythroid to myeloid transition. We report here on the
isolation of hemopoietic lineage switch 5 (Hls5), a gene
expressed by the monocytoid variant cells, but not the
parental J2E cells. Hls5 is a novel member of the RBCC
(Ring finger, B box, coiled-coil) family of genes, which
includes Pml, Herf1, Tif-1, and Rfp. Hls5 was expressed
in a wide range of adult tissues; however, at different
stages during embryogenesis, Hls5 was detected in the
branchial arches, spinal cord, dorsal root ganglia, limb
buds, and brain. The protein was present in cytoplas-
mic granules and punctate nuclear bodies. Isolation of
the human cDNA and genomic DNA revealed that the
gene was located on chromosome 8p21, a region impli-
cated in numerous leukemias and solid tumors. En-
forced expression of Hls5 in HeLa cells inhibited cell
growth, clonogenicity, and tumorigenicity. It is con-
ceivable that HLS5 is one of the tumor suppressor
genes thought to reside at the 8p21 locus.
Differentiated cells for each of the hemopoietic lineages de-
velop from pluripotent stem cells (1), a process orchestrated via
specific combinations of transcription factors (2, 3). Lineage-
restricted structural/functional genes are gradually expressed
as cells display the phenotype of mature cells. Although the
process of lineage commitment was once considered irrevoca-
ble, data over the past decade indicate that the hemopoietic
system may be more plastic than previously thought (4). Leu-
kemic cells apparently committed to one lineage can be “repro-
grammed” or undergo “lineage switching” and develop the ap-
pearance of another cell type (5, 6).
Early descriptions of lineage switching involved the conver-
sion of B lymphoma cells overexpressing the raf and myc on-
cogenes into macrophages (5, 7). Other B cell to macrophage
transitions involved a number of different oncogenes (8–11),
whereas mast cells transformed with Bcr-abl have produced
erythroid and megakaryocytic cells (12). A B cell to granulo-
cytic switch has also been observed previously (13). The recent
data with Pax5/ mice are particularly noteworthy as com-
mitted B cells lacking the Pax5 gene could develop into macro-
phages, osteoclasts, dendritic cells, granulocytes, natural killer
cells, and T cells upon appropriate stimulation (14, 15).
The combination and concentration of transcription factors
within hemopoietic cells play key roles in dictating lineage fate
(3, 16). Indeed, by manipulating the levels of transcription
factors, the plasticity of the hemopoietic system has been dem-
onstrated, e.g. increasing the concentration of GATA-1 in my-
elomonocytic cells produced thrombocytes, eosinophils, and
erythroblasts (6). Similarly, overexpression of GATA-1 or
NF-E2 in M1 monoblastoid cells generated erythroid and
megakaryocytic cells (17, 18). In addition, overexpression of
PU.1 in murine erythroleukemia cells induced an erythroid to
myeloid lineage switch (19).
One example of a spontaneous lineage switch was the con-
version of J2E erythroleukemic cells into monocytoid cells (20).
The parental J2E cells differentiated morphologically and syn-
thesized hemoglobin in response to erythropoietin (21, 22),
whereas the monocytic variants (J2E-m)1 lacked all of the
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erythroid characteristics and displayed myeloid surface mark-
ers (20). To search for genes involved in this breach of lineage
commitment, we have utilized cDNA representational differ-
ence analysis (RDA) (23). This PCR-based form of subtractive
hybridization identified hemopoietic lineage switch 7 (Hls7),
the murine homologue of human myeloid leukemia factor 1
(MLF1) (24, 25), as one molecule expressed exclusively in the
myeloid variant (23, 26). Ectopic expression of Mlf1 in parental
J2E cells recapitulated the phenotypic changes associated with
the erythroid to myeloid switch. Moreover, exogenous Mlf1
impeded the differentiation of normal and immortalized eryth-
roid cells and promoted myeloid maturation (23). These obser-
vations implicated Mlf1 as an important hemopoietic lineage-
determining gene.
In this study, we describe the isolation of Hls5 from the RDA
between J2E cells and a myeloid counterpart, J2E-m2. Hls5 is
a novel member of the Ring finger, B box, coiled-coil (RBCC)
family of genes, which includes the well characterized tumor
suppressor gene Pml (27) as well as Tif1- (28), Herf1 (29), and
Rfp (30). The human HLS5 gene mapped to chromosome 8p21,
a locus involved in numerous leukemias and cancers (31). Sig-
nificantly, expression of exogenous Hls5 suppressed the tumor-
igenic phenotype of HeLa cells. Therefore, it is plausible that
Hls5 is one of the tumor suppressor genes postulated to reside
at 8p21.
EXPERIMENTAL PROCEDURES
Cell Culture—Cells were maintained in Dulbecco’s modified Eagle’s
medium with 5% fetal calf serum, and cell viability was determined by
eosin exclusion (22). Total RNA and protein isolated from various tis-
sues and cell lines were analyzed by Northern blotting and immuno-
blotting as described previously (23, 32).
cDNA RDA—The RDA used was based on the method of Hubank and
Schatz (33) and modified as described previously (23). Poly(A) RNA
isolated from J2E driver and J2E-m2 tester cell lines was converted to
double-stranded DNA, digested with Sau3AI, and subjected to three
cycles of subtraction. Fragments enriched by this procedure were sub-
cloned into pGEM-T (Promega, Madison, WI) for further analysis.
cDNA and Genomic Library Screening—A cDNA library from the
murine lymphohematopoietic progenitor cell line EML C.115 (34) was
screened for full-length Hls5 using the RDA fragment as a probe. To
confirm that the 5 end of the cDNA had been isolated, a rapid analysis
of the cDNA ends (RACE) strategy was adopted using the Marathon
cDNA amplification kit (Clontech, Palo Alto, CA). A 129 SvJ murine
genomic library in Lambda DASH™ II (Stratagene, La Jolla, CA) was
screened for clones containing the Hls5 gene. The complete genomic
sequence was obtained from two independent clones. The human HLS5
cDNA was isolated from a human fetal liver cDNA library (Clontech BD
Biosciences), and two independent clones were sequenced.
Hls5 Constructs and Infection of HeLa Cells—A Myc epitope tag was
introduced at the C terminus of Hls5 and HLS5 and then subcloned into
pcDNA3 (Invitrogen) and pBabe-puromycin (35) to generate the
pcDNA3-Hls5-Myc, pcDNA3-HLS5-Myc, and pBabe-Hls5-Myc, respec-
tively. The PA317-packaging cell line (36) was transfected with linear-
ized pBabe-Hls5-Myc, and viral supernatants were used to infect HeLa
cells as described previously (32). Individual clones were isolated, and
unique viral integration sites were determined by Southern blotting.
Myc-tagged Hls5 was detected by immunoblotting using anti-Myc
(9E10) antibodies followed by horseradish peroxidase-conjugated anti-
bodies as described elsewhere (23, 32). Visualization was by enhanced
chemiluminescence (Amersham Biosciences).
Immunofluorescent Microscopy—COS-7 cells were transiently trans-
fected with pcDNA3-Hls5-Myc using LipofectAMINE (Invitrogen).
After 24 h, cells were incubated with anti-Myc antibodies (9E10)
before application of Alexa Fluor® 488 goat anti-mouse IgG (Molec-
ular Probes, Eugene, OR). After washing, coverslips were mounted in
2.5% 1,4-diazobicyclo[2.2.2]-octane (DABCO, Fluka, New South Wales,
Australia) containing 0.00005% Hoechst 33258 (Calbiochem). Fluores-
cence was visualized on a Bio-Rad MRC 1024 UV-laser scanning con-
focal microscope.
Clonogenicity and Tumorigenicity Assays—For clonogenicity assays,
a layer of 0.8% agar was placed in 6-cm dishes and then 104 HeLa cells
were seeded in a 0.3% agar layer as described above (37). Colonies were
counted 3 weeks after initial plating. Tumorigenicity was determined
by injecting 106 cells subcutaneously into 6–8-week-old female BALB/c
nude mice. Tumor volume was determined twice a week using calipers.
Cell Cycle and Apoptosis Analyses—HeLa cells transfected with vec-
tor alone, pcDNA3-Hls5-Myc, or pcDNA3-HLS5-Myc using Lipo-
fectAMINE 2000 were cultured for 24–72 h and then stained with
propidium iodide before analysis on a FACScanII instrument (BD Bio-
sciences) as described in detail elsewhere (22, 38). TUNEL (transferase
dUTP nick and label) assays were performed according to the manu-
facturer’s instructions (Roche Applied Science). Transfected HeLa cells
or those treated with nocodazole (100 ng/ml) were incubated overnight
before Cdk1 immunoprecipitation (anti-Cdc2 p34; sc-54, Santa Cruz
Biotechnology, Santa Cruz, CA) and assayed for kinase activity as we
have described previously (32) using [-32P]ATP and histone H1. Phos-
phorylated protein was separated by SDS-PAGE, transferred, and an-
alyzed by phosphorimaging device.
In Situ Hybridization and Fluorescent in Situ Hybridization—Whole
mount in situ hybridization on mouse embryos was performed as de-
scribed previously (39). A digoxigenin-labeled riboprobe was prepared
by transcription of a 903-bp fragment from the 3-untranslated region of
Hls5. For fluorescent in situ hybridization, a 2.4-kb fragment of the
human HLS5 gene was generated by PCR, labeled with biotin-14-dATP
and hybridized to metaphase spreads from two normal males using a
modification of the previously described technique (40). Images of met-
RDA, representational difference analysis; RBCC, Ring finger, B box,
coiled-coil; ERK, extracellular signal-regulated kinase; Pml, promyelo-
cytic leukemia; Rfp, ret finger protein; MAIR, macrophage-derived apo-
ptosis-inducing RBCC protein.
FIG. 1. RDA conducted between the erythroid (J2E) and a
myeloid (J2E-m2) cell types. A, the left panel shows the cDNA
representations generated prior to the analysis. The right panel shows
the eight individual clones obtained following three rounds of subtrac-
tion. B, homologies of Hls1–8 and expression patterns determined by
Northern blotting. nd, not determined; MW, molecular weight.
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FIG. 2. Hls5 is a novel member of the RBCC family. A, cDNA and amino acid sequence of murine Hls5. Sequence analysis of the cDNA
(nucleotides numbered above) identified a 501 amino acid open reading frame (amino acids numbered below). The various domains are boxed and
displayed at the right. B, structural organization of Hls5 and other members of the RBCC family of proteins. C, genomic structure of murine Hls5
with introns boxed. D, approximately 1 kb of Hls5 promoter region with potential transcription factor binding sites and predicted transcription
initiation site (TIS) identified. UTR, untranslated region.
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aphase preparations were captured by a cooled CCD camera using the
ChromoScan image collection and enhancement system (Applied Imag-
ing International Ltd.).
RESULTS
Isolation of Hls5, a Novel RBCC Family Member—In an
attempt to identify genes that were activated when J2E cells
became monocytoid, an RDA was conducted between the eryth-
roid and myeloid cell types. Fig. 1A shows the representations
from J2E and the myeloid variant J2E-m2. Following three
rounds of PCR-based subtraction, eight clones were isolated,
which were termed Hls1–8 (Fig. 1B). Hls1 and Hls6 repre-
sented previously characterized myeloid genes, whereas Hls7 is
the murine homologue of MLF1 (23–25). Hls3, Hls4, and Hls8
were not studied further because they included a mitochondrial
contaminant, a known signaling molecule and a concatamer.
When originally isolated, Hls2 was a novel molecule. Full-
length Hls2 was represented by a 1,716-bp cDNA and contained
an open reading frame encoding a protein of 433 amino acids
(GenBankTM accession numbers AF009513 and AAC17945).
However, overexpression and underexpression studies of Hls2
in a variety of hemopoietic cell lines failed to alter their phe-
notype. A yeast two-hybrid screen did not identify any binding
partners for Hls2. This gene was subsequently shown to have
88% identity and 92% homology with the secreted protein,
human plasma glutamate carboxypeptidase (41), and was not
analyzed further.
The 361-bp Hls5 fragment (GenBankTM accession number
AF009514) was used to screen a murine cDNA library, and
then RACE was employed to delineate the 5 end of the cDNA.
These approaches generated a 3,687-bp cDNA (GenBankTM
accession number AF145374) with a 501 amino acid open read-
ing frame (Fig. 2A). The putative translation initiation site
contained a consensus Kozak (42, 43) sequence.
Data base searches revealed that the predicted protein had
significant homology with several members of the RBCC family
of proteins (Fig. 2B). The highest similarity was found with the
Rfp (30, 44), SS-a/Ro-52 (45), and Herf1 proteins (29). In addi-
tion, these molecules contained an SPRY/B30.2/NHL domain
(46). Hls5 also displayed structural similarities to Pml (27) and
Tif1- (28) with the exception that these molecules have two
B-box domains and lack the SPRY region. KIAA1098 and
TRIM35 represent Hls5-related expressed sequence tags (47,
48). While this paper was in preparation, Kimura et al. (49)
reported the cloning of a cDNA induced by macrophage colony-
stimulating factor they named MAIR, which is identical
to Hls5.
Isolation of genomic clones revealed that the gene contained
six exons and five introns ranging in size from 728 bp to 5.6 kb
(Fig. 2C). Potential binding sites for numerous transcription
factors were identified within the putative promoter region
(Fig. 2D).
Expression of Hls5 and Intracellular Localization—Northern
blotting was used to determine the organs in which Hls5 was
expressed. Fig. 3A shows that Hls5 mRNA, 4 kb in length,
was detected in a wide variety of adult organs. Abundant
mRNA was present in brain, heart, kidney, spleen, skeletal
muscle, and thymus with lower levels found in stomach, large
intestine, and bone marrow. Interestingly, Hls5 was not detect-
able in adult liver, whereas it was present in fetal liver.
As Hls5 was isolated from an erythroid to myeloid lineage
switch, the expression pattern of Hls5 was examined in a panel
of hemopoietic cell lines (Fig. 3B). Although the levels varied
considerably, Hls5 mRNA was present in most erythroid, my-
eloid, and lymphoid lines tested; however, the transcript was
not detected in J2E cells or the pre-B cell line 1-Bra. The
difference in Hls5 expression between J2E cells and other
erythroleukemic lines (F4N, 707) could be attributed to immor-
talization of these cells at different stages of red cell matura-
tion in which J2E cells displayed a more mature phenotype
than the other erythroid lines (23).
The predicted molecular mass of the Hls5 protein was 59
kDa; however, immunoblotting of transfected COS cells iden-
tified a 66-kDa protein (Fig. 3C). The endogenous protein could
not be detected in a variety of cell lines, presumably because of
low levels of expression.
Indirect immunofluorescence and confocal microscopy were
then employed to determine the intracellular location of Hls5
FIG. 3. Expression of Hls5 and subcellular localization. A,
Northern blot of total RNA from different organs in adult mice. Glyc-
eraldehyde-3-phosphate dehydrogenase (Gapdh) was used as a loading
control. B, Northern blot of total RNA extracted from murine hemopoi-
etic cell lines. C, COS cells were transfected with pcDNA-Hls5-Myc (1–4
g) and the protein identified by immunoblotting (IB) with anti-myc
antibodies. The blot was reprobed with anti-ERK2 antibodies, which
served as a loading control. D, COS and HeLa cells were transfected
with pcDNA-Hls5-Myc, and 24 h later, the protein was localized by
confocal microscopy using an anti-Myc antibody. DNA was identified by
Hoescht staining.
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protein. As the antisera produced to Hls5 were unable to detect
the subcellular localization of the endogenous protein, COS and
HeLa cells were transiently transfected with a Myc-tagged
Hls5 construct. Fig. 3D shows that Hls5 protein was detected in
discrete cytoplasmic granules as well as punctate nuclear bod-
ies. The cytoplasmic localization did not coincide with markers
for Golgi, mitochondria, or lysosomes, and the nuclear spots
were not PML bodies (data not shown). In cells expressing
higher levels of Hls5, the protein also concentrated in the
perinuclear region. Similar subcellular compartmentalization
of Hls5 was observed in NIH3T3 and 293T cells (data not
shown).
Expression of Hls5 during Embryogenesis—To pursue the
expression profile of Hls5 during embryogenesis, whole mount
in situ hybridization analysis was performed over a range of
embryonic stages. At 10.5 days post-coitum (dpc), Hls5 expres-
sion was detected in branchial arches 1 and 2 and the fronto-
nasal process, limb buds, spinal cord, and dorsal root ganglia
(Fig. 4). There was also evidence of relatively weak somite-
associated staining. Hemi-sectioning of the embryo confirmed
staining in the dorsal root ganglia and revealed that neural
expression was predominantly in the dorsal half of the spinal
cord, although weaker expression was also detected in the
ventral region (data not shown). At 12.0 dpc, Hls5 was ex-
pressed primarily in the limbs and transiently in the develop-
ing eye. By 13.5 dpc, expression in the limb was restricted to
the interdigital regions and expression was evident in the
telencephalic region of forebrain. This analysis suggests that
expression of Hls5 in the developing embryo is far more re-
stricted than that seen in adult organs.
Human HLS5 Localizes to Chromosome 8p21—A full-length
human cDNA was isolated (GenBankTM accession number
AF492463), and low levels of mRNA were detected in a number
FIG. 4. Expression of Hls5 in murine
embryos. Whole mount in situ hybridiza-
tion analysis of embryos at various dpc is
shown. ba1, branchial arch 1; ba2, bran-
chial arch 2; fnp, frontonasal process; fl,
forelimb; hl, hind limb; drg, dorsal root
ganglia; sc, spinal cord; e, eye; fb,
forebrain.
FIG. 5. HLS5 localizes to chromosome 8p21.1. A, Northern blot of
RNA extracted from different human organs. -actin was used as a
loading control. B, chromosomal localization of HLS5 by fluorescent in
situ hybridization of human metaphase spreads. C, DNA data base and
chromosome map analysis identified HLS5 between markers D8S131
and D8137GT.
FIG. 6. Hls5 suppresses HeLa cell growth. A, immunoblot (IB)
analysis of parental HeLa cells and individual HeLa cell clones infected
with retroviral Myc-tagged Hls5 or vector alone. Transiently trans-
fected COS cells were used as a positive control. B, growth rate of
representative HeLa clones over 4 days. Each value shown is the
mean  S.D. (n  3). *, p  0.05.
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of human organs and tissues (Fig. 5A). A 2.4-kb human
genomic fragment (GenBankTM accession number AF494189)
was used for fluorescent in situ hybridization, which showed
that the gene was located on chromosome 8p21.1 (Fig. 5B). An
analysis of the DNA databases and chromosome maps showed
that expressed sequence tag KIAA1098 (47), which is identical
to human HLS5, resided between markers D8S137GT and
D8S131 (Fig. 5C). These data confirm that HLS5 is located at
8p21.1, a region that has been implicated in numerous leuke-
mias and solid tumors, and is thought to contain at least one
tumor suppressor gene (31).
Hls5 Suppresses HeLa Cell Growth and Tumorigenicity—As
HLS5 resides within a tumor suppressor locus and is related to
the known tumor suppressor gene Pml, which restricts cell
growth (27, 37), the effects of ectopic Hls5 expression were
investigated in HeLa cells. Using a retroviral vector, Hls5
protein expression was increased in several independent HeLa
transfectants (Fig. 6A). Each clone expressing Hls5 grew
slower (Fig. 6B) and generated fewer colonies in soft agar (Fig.
7, A and B). Significantly, the development of tumors in nude
mice was reduced substantially in cells transfected with Hls5
(Fig. 7C). Together, these data indicate that Hls5 is capable of
inhibiting the growth and tumorigenic phenotype of HeLa cells
and is therefore a candidate tumor suppressor gene within the
8p21 locus.
It is noteworthy that within a few weeks of culture, Hls5
protein could no longer be detected in each of the Hls5 trans-
fectants (data not shown). To circumvent the problem of re-
duced Hls5 expression following stable transfection, HeLa cells
were also transiently transfected with Hls5. Fig. 8A shows that
cells accumulated in G2/M phase of the cell cycle, indicating
that one mechanism by which Hls5 may inhibit cell growth is
by impeding passage through the cell cycle. Similar to nocoda-
zole, a G2/M inhibitor, Hls5 increased the activity of cdk1 (Fig.
8B); however, no significant changes were observed in the
levels of p53, cyclins A, B1, or E, Cdk1, Cdk2, p21
waf1, p27kip1,
and p57kip2 or the tyrosine phosphorylation status of Cdk1
(data not shown).
Human HLS5 induced a similar build up of HeLa cells in
G2/M 30 h post-transfection (Fig. 8C). Significantly, overex-
pression of both the murine and human genes ultimately led to
increased cell death. Fig. 8C shows a marked accumulation of
sub-G1 DNA 70 h after transfection, indicative of DNA break-
down and apoptosis. This effect was dependent on the level of
HLS5, increasing the amount transfected correlated well with
the degree of DNA degradation until saturation was reached
(Fig. 8D). The increase in sub-G1 DNA coincided with reduced
cell viability and increased TUNEL-positive cells (Fig. 8E).
These data demonstrate that HLS5 overexpression induces cell
death. Thus, the growth inhibitory effects of Hls5 may result
from a combination of delayed transit through the cell cycle and
elevated cell death.
FIG. 7. Hls5 suppresses HeLa clono-
genicity and tumorigenicity. A, the
clonogenicity of various HeLa cell trans-
fectants was determined using soft agar.
B, colony formation of HeLa cell clones as
a percentage of cells plated. C, tumor vol-
ume of HeLa cell clones injected into nude
mice. Each value shown in panels B and C
is the mean  S.D. (n  3). *, p  0.01.
Hls5, a Potential Tumor Suppressor Gene8186
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
DISCUSSION
In this paper, we report on the isolation of Hls5, a novel gene
that was induced when the erythroleukemic J2E cell line spon-
taneously developed a myeloid phenotype. Hls5 is a new mem-
ber of the growing family of RBCC proteins. Other members
include Pml (27), Herf1 (29), TIF1- (28, 50), SS-A/Ro (45), and
Rfp (30, 44). The tripartite organization of the RBCC domains
is evolutionarily conserved, suggesting that these proteins
have functional similarities (48). It has been proposed that the
coiled-coil domain of the RBCC family is required for ho-
modimerization, whereas the other motifs are involved in re-
cruitment of additional proteins, which specify intracellular
compartmentalization (48). The subcellular localization of Hls5
in cytoplasmic granules and nuclear bodies is similar to that
observed with a striking number of RBCC proteins (44, 48).
Whereas these cytoplasmic vesicles or speckles remain unde-
fined, some punctate nuclear structures have been well char-
acterized, e.g. PML bodies (27, 51).
Pml, Rfp, and Tif-1 are RBCC family members involved in
chromosomal translocations, which induce neoplasms (50, 52–
55), with PML being recognized as a bona fide tumor suppres-
sor gene (27, 37, 38, 56). Efp, another RBCC family member, is
associated with the development of breast cancer (57). The
localization of human HLS5 to chromosome 8p21 is significant
because this locus is implicated in several leukemias and solid
tumors. It has been proposed that one or more tumor suppres-
sor genes reside on the short arm of chromosome 8 (31, 58–65).
This region has been associated with numerous cancers includ-
ing prostate, breast, lung, bladder, ovary, and liver (58, 59, 61,
62, 64–68). Importantly, three studies on liver, breast, and
colon cancer have mapped a deleted region, which overlaps
with the location of HLS5 (59, 62, 68). Like Pml (69), Hls5 was
able to reduce the growth of HeLa cells, inhibit colony forma-
tion, and suppress tumor development, indicating that HLS5 is
a potential tumor suppressor gene at this locus.
The reduced growth and tumorigenicity of HeLa cells ex-
pressing exogenous Hls5 may be explained, at least in part,
by the accumulation of cells in G2/M. Impaired transit
through the cell cycle could result in Hls5-expressing cells
displaying slower growth rates. Additionally, overexpression
of Hls5 induced apoptosis in HeLa cells. This observation is
compatible with the independent isolation of HLS5 as MAIR,
a pro-apoptotic molecule in TF-1 and NIH3T3 cells. MAIR
reduced mitochondrial membrane potential and activated
caspases 7, 8, and 9 but not caspase 3; however, additional
studies are required to define the precise biochemical mech-
anisms for Hls5/MAIR-inducing cell death (49). It is possible
that the effects of Hls5 are concentration-dependent, i.e. at
lower levels, Hls5 interferes with cell cycle passage, whereas
at higher concentrations the protein promotes cell death.
Alternatively, restricting movement through the cell cycle
may be a prelude to apoptosis. Therefore, a loss of a gene at
8p21.1, which affects the G2/M transition and apoptosis, is
potentially deleterious to cells.
FIG. 8. Hls5 slows cell cycle and induces apoptosis. A, cell cycle
analysis of HeLa cells transfected with Hls5 (gray line) or vector alone
(black line). B, HeLa cells were either transfected with vector alone or
Hls5 or treated with nocodazole. Cells were lysed 24 h later, and then
Cdk1 was immunoprecipitated and assayed for kinase activity using
[-32P]ATP and histone H1. C, cell cycle analysis of HeLa cells trans-
fected with murine Hls5 or human HLS5, 30 and 70 h post-transfection.
D, increasing amounts (1–4 g) of HLS5 DNA were transfected into
HeLa cells, and the percentage of cells with sub-G1 DNA content was
determined after 72 h. Immunoblotting (IB) of cell lysates revealed that
the amount of HLS5 protein present in the cells compared with the
loading control ERK2. Each value is the mean  S.D. (n  3). p 
0.0001 (ANOVA, analysis of variance). E, HeLa cell death after trans-
fection with Hls5 or vector alone was determined by eosin exclusion,
whereas DNA degradation was demonstrated by TUNEL staining. *,
p  0.05. Each value is the mean  S.D. (n  3).
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It is noteworthy that Hls5 was isolated from an erythroid to
myeloid lineage switch and MAIR was cloned as a gene induced
by macrophage colony-stimulating factor (49). The expression
of Hls5 in bone marrow, spleen, and fetal liver is consistent
with a role for this gene in hemopoiesis. Significantly, dele-
tions, translocations, and inversions of 8p21 have resulted in
acute myeloid leukemias (70) and a loss of this region has been
implicated as a secondary event producing a worse prognosis in
Mantle cell lymphoma (60). Intriguingly, the 8p21 locus is also
involved in a t(8;17) (p21;q21), which produces rare acute pro-
myelocytic leukemias (71, 72). Although the vast majority of
acute promyelocytic leukemias are caused by the t(15;17) in-
volving PML-RAR (27, 73), several variant translocations
have been identified previously (73, 74). It is tempting to spec-
ulate that HLS5 could be involved in the t(8;17) abnormality.
Although Hls5 was expressed very widely in adult organs,
the developmental expression profile was intriguing. In the
embryo Hls5, mRNA was expressed predominately in the facial
primordia, limbs, spinal cord, brain, and dorsal root ganglia.
Hls5 transcripts were also detected in the somites and the eye.
Expression in these sites of the developing embryo suggests
that Hls5 may be involved in remodeling of tissues and/or
apoptosis. These observations support the notion that Hls5/
MAIR may be pro-apoptotic (49) and that this effect may be cell
type-specific. The role of Hls5 in development may become
clearer with the completion of Hls5/ mice.
It is interesting to note that two of the genes obtained from
the erythroid to myeloid lineage switch are implicated in cancer
development. Hls7 (23) was also identified as MLF1, a novel
oncogene involved in translocations between chromosomes 3
and 5, that causes acute myeloid leukemias (24). Furthermore,
elevated levels of wild type MLF1 have been observed in non-
t(3;5) leukemias and are associated with poor prognosis (75).
Conversely, HLS5 bears features of a tumor suppressor gene. It
would appear that the RDA performed on this hemopoietic
lineage switch has isolated two important genes, which when
dysregulated may induce neoplasia.
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